Immuneering Corp (IMRX)
2.46
+0.08
(+3.36%)
USD |
NASDAQ |
Oct 04, 16:00
2.48
+0.02
(+0.81%)
After-Hours: 20:00
Immuneering SG&A Expense (TTM): 16.62M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 16.62M |
March 31, 2024 | 16.42M |
December 31, 2023 | 16.68M |
September 30, 2023 | 16.40M |
June 30, 2023 | 16.37M |
March 31, 2023 | 16.03M |
December 31, 2022 | 15.60M |
September 30, 2022 | 14.64M |
Date | Value |
---|---|
June 30, 2022 | 13.40M |
March 31, 2022 | 11.04M |
December 31, 2021 | 8.272M |
September 30, 2021 | 6.261M |
June 30, 2021 | 4.361M |
March 31, 2021 | 3.65M |
December 31, 2020 | 3.11M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
3.11M
Minimum
Dec 2020
16.68M
Maximum
Dec 2023
11.92M
Average
14.64M
Median
Sep 2022
SG&A Expense (TTM) Benchmarks
Singular Genomics Systems Inc | 53.22M |
Biomarin Pharmaceutical Inc | 987.94M |
Integra Lifesciences Holdings Corp | 686.35M |
Eton Pharmaceuticals Inc | 19.66M |
Tenon Medical Inc | 13.13M |